Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Christine K. Moore

2 papers in the library · 172 citations · publishing 2019-2026

Papers

Chemical evidence for the use of multiple psychotropic plants in a 1,000-year-old ritual bundle from South America.

Proceedings of the National Academy of Sciences of the United States of America June 4, 2019 Melanie J Miller, Juan Albarracin-Jordan, Christine K. Moore et al. 171 citations

Chemical analysis of a ritual bundle from a Bolivian rock shelter, dated to about 1,000 C.E., detected traces of bufotenine, dimethyltryptamine, harmine, and cocaine (with its breakdown product benzoylecgonine). These compounds come from at least three different psychoactive plants, including the two key ingredients of ayahuasca—harmine and dimethyltryptamine—found together in a single artifact for the first time in this region. The plants originated from distant and ecologically distinct areas of South America, indicating that hallucinogenic substances were traded or transported over long distances. This suggests that pre-Columbian peoples possessed sophisticated botanical knowledge and incorporated such plants into shamanic rituals.

Toward a framework for psychedelic clinical trials in adolescents

Child and Adolescent Psychiatry and Mental Health March 10, 2026 Christine K. Moore, Henry Riordan, Rolana Avrumson et al. 1 citation

Psychedelic therapies show promise for adult mental health conditions, and there is growing interest in testing them in adolescents, who often experience these disorders earlier in life. Regulatory agencies are expected to require trials in younger populations after adult approvals. This paper outlines key considerations for designing and conducting such trials, including safeguards and best practices tailored to adolescents. It builds on adult trial methods and emphasizes increased psychological support and rigorous oversight. The goal is to ensure future adolescent trials are safe, ethical, and meet high scientific and regulatory standards, fostering patient-focused dialogue.